Current Report Filing (8-k)
March 26 2020 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): March 26, 2020
TFF PHARMACEUTICALS,
INC.
(Exact Name of Registrant as Specified in Its
Charter)
Delaware
|
|
001-39102
|
|
82-4344737
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
|
|
|
|
|
2600 Via Fortuna, Suite 360
Austin, Texas 78746
|
(Address of principal executive offices)
|
(737) 802-1973
|
(Registrant’s telephone number, including area code)
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following
provisions.
|
☐
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
|
|
☐
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b)of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock: Par value $.001
|
|
TFFP
|
|
Nasdaq Capital Market
|
Item 2.02 Results of Operations and
Financial Condition.
On March 26, 2020, TFF
Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter
and fiscal year ended December 31, 2019. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is
incorporated herein by reference.
The information in this
Item 2.02, including the press release attached as Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 but shall
not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it
be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether
made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d)
|
Exhibits
|
Method Filing
|
The following exhibit is furnished with this report:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
TFF PHARMACEUTICALS, INC.
|
|
|
Dated: March 26, 2020
|
/s/ Glenn
Mattes
|
|
Glenn Mattes,
|
|
President and Chief Executive Officer
|
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024